Xeljanz woes are likely to be boost to Rinvoq, which is already growing fast – making $450 million in the first nine months of 2020, including $215 million in the third quarter alone.

Pfizer’s Xeljanz pill has been approved in the US in psoriatic arthritis, for people who have not responded to, or cannot take, other disease-modifying drugs. Xeljanz has been FDA-approved since ...